Article
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
British journal of cancer - 12 Jul 2016
Cha Yongjun, Kim Kyung-Ju, Han Sae-Won, Rhee Ye Young, Bae Jeong Mo, Wen Xianyu, Cho Nam-Yun, Lee Dae-Won, Lee Kyung-Hun, Kim Tae-Yong, Oh Do-Youn, Im Seock-Ah, Bang Yung-Jue, Jeong Seung-Yong, Park Kyu Joo, Kang Gyeong Hoon, Kim Tae-You
Abstract excerpt
BACKGROUND: The association between the CpG island methylator phenotype (CIMP) and clinical outcomes in metastatic colorectal cancer remains unclear. We investigated the prognostic impact of CIMP in patients with metastatic colorectal cancer treated with systemic chemotherapy. METHODS: Eight CIMP-specific promoters (CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CDKN2A, CRABP1, and MLH1) were examined. The CIMP status was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
